Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing innovative products for difficult-to-treat skin diseases and conditions where autologous fibroblasts with or without genetic modification can play a key role in addressing unmet medical needs, today announced that David Pernock, Chairman and Chief Executive Officer, Fibrocell Science, will present at the Rodman & Renshaw 15th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
Help employers find you! Check out all the jobs and post your resume.
